-
Something wrong with this record ?
Chemical aspects of pharmacological prophylaxis against nerve agent poisoning
J. Bajgar, J. Fusek, J. Kassa, K. Kuča, D. Jun
Language English Country Netherlands
Document type Review, Research Support, Non-U.S. Gov't
- MeSH
- Acetylcholinesterase chemistry metabolism MeSH
- Chemical Warfare Agents chemistry poisoning MeSH
- Cholinergic Antagonists pharmacology chemistry MeSH
- Cholinesterase Inhibitors pharmacology chemistry poisoning MeSH
- Humans MeSH
- Organophosphates chemistry MeSH
- Organophosphate Poisoning MeSH
- Poisoning prevention & control MeSH
- Cholinesterase Reactivators pharmacology chemistry MeSH
- Check Tag
- Humans MeSH
- Publication type
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
Prophylactic approaches against intoxication with organophosphates (OP)/nerve agents can be based on following principles: keeping acetylcholinesterase (AChE), the key enzyme for toxic action of OP/nerve agents, intact (protection of cholinesterases) is a basic requirement for effective prophylaxis. It can be reached using simple chemicals such as reversible inhibitors (preferably carbamates), which are able to inhibit AChE reversibly. AChE inhibited by carbamates is resistant to OP/nerve agent inhibition. After spontaneous recovery of the activity, normal AChE serves as a source of the active enzyme. Detoxification is realised by administration of the enzymes splitting the OP or exploitating specific enzymes (cholinesterases). OP/nerve agent is bound to the exogenously administered proteins (enzymes) and, thus, the agent level in the organism is decreased ("scavenger" effect). The antidotes currently used for the treatment of OP poisoning (also simple chemicals) can be tested as prophylactics. This principle can be considered as a treatment "in advance". The problem with their use is the timing, duration and achievement of sufficient levels of these antidotes after the administration. At present, PYRIDOSTIGMINE seems to be common prophylactic antidote; prophylactics PANPAL (tablets with pyridostigmine, trihexyphenidyle and benactyzine), TRANSANT (transdermal patch containing HI-6) are other means introduced into different armies as prophylactics. Future development will be focused on scavengers (cholinesterases and other enzymes) acting before the binding of nerve agent to the target sites, and on other drugs reversible cholinesterase inhibitors (e.g. huperzine A, physostigmine, acridine derivatives etc.) including non-traditional routes of administration.
References provided by Crossref.org
- 000
- 03603naa 2200433 a 4500
- 001
- bmc11022985
- 003
- CZ-PrNML
- 005
- 20121127124104.0
- 008
- 110801s2009 ne e Eng||
- 009
- AR
- 024 __
- $a 10.2174/092986709788803088 $2 doi
- 035 __
- $a (PubMed)19689278
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Bajgar, Jiří, $d 1944- $7 js20020122033
- 245 10
- $a Chemical aspects of pharmacological prophylaxis against nerve agent poisoning / $c J. Bajgar, J. Fusek, J. Kassa, K. Kuča, D. Jun
- 314 __
- $a Department of Toxicology, Faculty of Military Health Sciences, University of Defense, Trebesska 1575, Hradec Kralove, Czech Republic. bajgar@pmfhk.cz
- 520 9_
- $a Prophylactic approaches against intoxication with organophosphates (OP)/nerve agents can be based on following principles: keeping acetylcholinesterase (AChE), the key enzyme for toxic action of OP/nerve agents, intact (protection of cholinesterases) is a basic requirement for effective prophylaxis. It can be reached using simple chemicals such as reversible inhibitors (preferably carbamates), which are able to inhibit AChE reversibly. AChE inhibited by carbamates is resistant to OP/nerve agent inhibition. After spontaneous recovery of the activity, normal AChE serves as a source of the active enzyme. Detoxification is realised by administration of the enzymes splitting the OP or exploitating specific enzymes (cholinesterases). OP/nerve agent is bound to the exogenously administered proteins (enzymes) and, thus, the agent level in the organism is decreased ("scavenger" effect). The antidotes currently used for the treatment of OP poisoning (also simple chemicals) can be tested as prophylactics. This principle can be considered as a treatment "in advance". The problem with their use is the timing, duration and achievement of sufficient levels of these antidotes after the administration. At present, PYRIDOSTIGMINE seems to be common prophylactic antidote; prophylactics PANPAL (tablets with pyridostigmine, trihexyphenidyle and benactyzine), TRANSANT (transdermal patch containing HI-6) are other means introduced into different armies as prophylactics. Future development will be focused on scavengers (cholinesterases and other enzymes) acting before the binding of nerve agent to the target sites, and on other drugs reversible cholinesterase inhibitors (e.g. huperzine A, physostigmine, acridine derivatives etc.) including non-traditional routes of administration.
- 590 __
- $a bohemika - dle Pubmed
- 650 _2
- $a acetylcholinesterasa $x chemie $x metabolismus $7 D000110
- 650 _2
- $a chemické bojové látky $x chemie $x otrava $7 D002619
- 650 _2
- $a cholinergní antagonisté $x farmakologie $x chemie $7 D018680
- 650 _2
- $a cholinesterasové inhibitory $x farmakologie $x chemie $x otrava $7 D002800
- 650 _2
- $a reaktivátory cholinesterasy $x farmakologie $x chemie $7 D002801
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a organofosfáty $x chemie $7 D010755
- 650 _2
- $a otrava $x prevence a kontrola $7 D011041
- 650 _2
- $a otrava organofosfáty $7 D062025
- 655 _2
- $a přehledy $7 D016454
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Fusek, Josef, $d 1945- $7 nlk20000076283
- 700 1_
- $a Kassa, Jiří, $d 1956- $7 mzk2003181395
- 700 1_
- $a Kuča, Kamil, $d 1978- $7 xx0041831
- 700 1_
- $a Jun, Daniel, $d 1976- $7 xx0040498
- 773 0_
- $t Current Medicinal Chemistry $w MED00001274 $g Roč. 16, č. 23 (2009), s. 2977-2986 $x 0929-8673
- 910 __
- $a ABA008 $b x $y 2
- 990 __
- $a 20110802092945 $b ABA008
- 991 __
- $a 20121127124130 $b ABA008
- 999 __
- $a ok $b bmc $g 881841 $s 732914
- BAS __
- $a 3
- BMC __
- $a 2009 $b 16 $c 23 $d 2977-2986 $m Current medicinal chemistry $n Curr Med Chem $i 0929-8673 $x MED00001274
- LZP __
- $a 2011-4B09/jvme